Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00901342 · ClinicalTrials.gov registry record · Phase 2
Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Dendreon.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
- 18
- Study locations
NCT00901342: Completed Phase 2 study of Prostate Cancer, sponsored by Dendreon.
NCT00901342 is a Phase 2 study of Prostate Cancer that has completed, run by Dendreon. The registered enrollment target is 104 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (83% lower). The trial reports 18 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00901342, a Phase 2 study of Prostate Cancer, has completed, sponsored by Dendreon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a Multicenter, Open Label, Phase 2 Study of Sipuleucel-T in Men with Metastatic Castrate Resistant Prostate Cancer (CRPC).
Conditions Studied
Interventions
- BIOLOGICAL sipuleucel-T
Study Locations (18)
New York
- NYU Cancer Institute - New York
- Mount Sinai School of Medicine Department of Urology - New York
- Columbia University Medical Center - New York
Illinois
- The University of Chicago Medical Center - Chicago
- Oncology Specialists, S.C. - Park Ridge
Maryland
- Hematology Oncology Consultants - Greenbelt
- Myron I. Murdock MD LLC - Greenbelt
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Indiana
- Indiana University Department of Urology - Indianapolis
Maine
- Maine Center for Cancer Medicine - Scarborough
New Jersey
- John Theurer Cancer Center at Hackensack - Hackensack
North Carolina
- GU Oncology Research Program - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2009-10 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
What the finished NCT00901342 record still lists
NCT00901342 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which sipuleucel-T is the first listed.
NCT00901342 lists 18 locations in 14 states (New York, Illinois, Maryland).
Frequently Asked Questions
What is clinical trial NCT00901342 about?
NCT00901342 is a clinical study titled "Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer". This is a Multicenter, Open Label, Phase 2 Study of Sipuleucel-T in Men with Metastatic Castrate Resistant Prostate Cancer (CRPC).
What is the current status of trial NCT00901342?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2009-10. Estimated completion is 2015-06.
What conditions does trial NCT00901342 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00901342?
The interventions under investigation include: sipuleucel-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT00901342?
This trial is sponsored by Dendreon, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00901342 being conducted?
This trial has 18 study locations across District of Columbia, Illinois, Indiana, Maine, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00901342's enrollment target sits among peer trials
104 326th of 735 higher than 410 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia